5α-Reductase inhibitors/finasteride

Prostate

Volumn 28, Issue 3 SUPPL. 6, 1996, Pages 82-87

  Stoner, Elizabeth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 reductase inhibitors; BPH; finasteride; prostate enlargement

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; URINE FLOW RATE;

EID: 0029897883     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(1996)6+<82::aid-pros16>3.0.co;2-n     Document Type: Conference Paper

References (28)

1. Cabot AT: The question of castration for enlarged prostate. Ann Surg 24:265, 1896.
2. White JW: The results of double castration in hypertrophy of the prostate. Ann Surg 22:1, 1895.
3. Peters CA, Walsh PC: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599-604, 1987.
4. Schröder FH, Westerhof M, Bosch JR, Kurth KH: Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserlin: A report of 6 cases. Eur Urol 12:318-321, 1986.
5. Graversen PH, Gasser TC, Wasson JH, Hinman F, Bruskewitz: Controversies about indications for transurethral resection of the prostate. J Urol 141:475-481, 1989.
6. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5α-reductase deficiency in man: An inher-ited form of male pseudohermaphroditism. Science 186:1213, 1974.
7. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, Macdonald PC, Wilson JD: Familial incomplete male pseudohermaphroditism type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291:944-949, 1974.
8. Imperato-McGinley J, Peterson RE, Gautier T, Shackleton C, Arthur A: Decreased urinary C19 and C21 steroid 5α-metabolites in parents of male pseudohermaphrodites with 5α-reductase deficiency-Detection of carriers. J Clin Endocrinol Metab 60:553-558, 1985.
9. Imperato-McGinley J, Gautier T: Inherited 5α-reductase deficiency in man. Trends Genet 2:130-133, 1986.
10. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW: Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 90:799-809, 1992.
11. Russell DW, Wilson JD: Steroid 5α-reductase: Two genes/two enzymes. Annu Rev Biochem 63:25-61, 1994.
12. Imperato-McGinley J, Peterson RE, Gautier T, Sturla A: Male pseudohermaphroditism secondary to 5α-reductase deficiency: A model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 11:637-645, 1979.
13. Fratianni CM, Imperato-McGinley J: The syndrome of 5α-reductase deficiency. Endocrinologist 4:302-314, 1994.
14. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez De Arellano E, Kazam E: Prostate visualization studies in males homozygous and heterozygous for 5α-reductase. J Clin Endocrinol Metab 75:1022-1026, 1992.
15. Rittmaster RS: Finasteride. N Engl J Med 330:120-125, 1994.
16. Stoner E, Guess H: Treatment of benign prostatic hyperplasia with 5α-reductase inhibitors. Endocrinologist 5:140-146, 1995.
17. Stoner E, Finasteride Study Group: Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43:284-294, 1994.
18. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74:505-508, 1992.
19. Gellar J: Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 71:1552-1555, 1990.
20. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan DA, Pappas F, Taylor A, Binkowitz B, Ng J, Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327:1185-1191, 1992.
21. Imperato-McGinley J, Shackleton C, Orlic S, Stoner E: C19 and C21 5beta/5alpha metabolite ratios in subjects treated with the 5alpha-reductase inhibitor MK-906-Comparison with male pseudo-hermaphrodites with inherited 5alpha-reductase deficiency. J Clin Endocrinol Metab 70:777-782, 1990.
22. Tenover JS, Zeitner ME, Plymate SR: Effects of 24-week administration of 5a-reductase inhibitor (MK-906) on serum levels of testosterone (T), free T and gonadotrophins, in man. Abstracts, 71st Annual Meeting Endocrine Soci (Seattle, Washington) 1989, abstract 583.
23. Finasteride Study Group, Stoner E: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291-299, 1993.
24. Ball AJ, Feneley RCL, Abrams PH: The natural history of untreated "prostatism." Br J Urol 53:613-616, 1981.
25. Bolognese JA, Kozioh RC, Kunitz SC, Grino PB, Patrick DL, Stoner E: Validation of a symptom questionnaire for benign prostatic hyperplasia. Prostate 21:247-254, 1992.
26. Guess HA, Jacobsen SJ, Girman CJ, Oesterling JE, Chute CG, Panser LA, Lieber MM: The role of community-based longitudinal studies in evaluating treatment effects - Example: Benign prostatic hyperplasia. Med Care 33(Supp):AS26-AS35 (1995).
27. McConnell JD, Barry MJ, Bruskewitz RC: "Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline Number 8." AHCPR publication no. 94-0582. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. February, 1994.
28. Barry MJ, Mulley AG, Fowler FJ Jr, Wennberg JW: Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA 259:3010-3017, 1988.